tiprankstipranks
Trending News
More News >

Opus Genetics initiated with a Buy at Lucid Capital

Lucid Capital analyst Dev Prasad initiated coverage of Opus Genetics (IRD) with a Buy rating and $5 price target The company’s lead program, OPGx-LCA5, is being evaluated in a Phase 1/2 trial for LCA5-associated Leber congenital amaurosis, which affects approximately 200 patients in the U.S., the analyst tells investors in a research note. The firm says Interim adult data have shown “encouraging” safety and efficacy results, and the ongoing pediatric cohort could provide additional validation, with initial data from all three pediatric patients expected in Q3.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1